Back to Results
Study to Investigate DSTA4637S in Participants With Staphylococcus Aureus Bacteremia
||Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
Blood Stream Infection, MRSA, Staphylococcus aureus
||Yoav Golan, MD
The purpose of this study is to test the safety of DSTA4637S, an investigational drug, at different dose levels and to find out what effects, good or bad, DSTA4637S, has on you while treating the S. aureus infection in your blood. DSTA4637S will be given in addition to the antibiotics you are already receiving for your S. aureus infection.
DSTA4637S is an investigational antibiotic to treat serious infections caused by the bacteria S. aureus. DSTA4637S is an experimental drug, which means that the Food and Drug Administration (FDA) or other health authorities that regulate new drugs have not approved DSTA4637S for the treatment of S. aureus bacteremia, except for testing in clinical trials.
- positive blood culture for S. aureus.
- Expected treatment with anti-staphylococcol standard of care antibiotics for at least 4 weeks.
- Body Mass Index between 18 to 32 kg/m2
- Known rifampicin resistant S. aureus bacteremia.
- Pregnancy/breast feeding.
- Presence of an intravascular catheter not planned to be removed.